ERBB2 and breast cancer: In addition, a French study (NCT02433067) has been initiated in patients undergoing systemic adjuvant treatment for early HER2-positive breast cancer, where patients are randomized between physical activity or standard of care; change in LVEF from baseline to 6 months after treatment start is primary endpoint of this trial.